DGIdb - ALEMTUZUMAB Drug Record

ALEMTUZUMAB chembl:CHEMBL1201587 ApprovedAntineoplasticImmunotherapy

Alternate Names:

GZ-402673
GZ402673
CAMPATH MABCAMPATH, LEMTRADA
ALEMTUZUMAB (GENETICAL RECOMBINATION)
ALEMTUZUMAB
CAMPATH
CAMPATH MABCAMPATH
LDP-03
LEMTRADA
MABCAMPATH
CAMPATH-1H
chembl:CHEMBL1201587
chemidplus:216503-57-0
drugbank:00087
rxcui:117055

Drug Info:

Year of Approval	2001
Drug Class	antineoplastic agents
FDA Approval	B-cell chronic lymphocytic leukemia
Drug Class	Therapeutic Antibodies
Drug Categories	blood proteins
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
Drug Categories	antibodies, monoclonal, humanized
Drug Categories	antineoplastic agents, immunological
Drug Categories	cd52-directed antibody interactions
Drug Categories	cd52-directed cytolytic antibody
Drug Categories	narrow therapeutic index drugs

(6 More Sources)

Publications:

White AL et al., 2013, FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs., Cancer Immunol Immunother
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Rebello et al., 1999, Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection., Transplantation
Wing et al., 1996, Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells., J. Clin. Invest.
Rawstron et al., 1999, The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment., Br. J. Haematol.
Geissinger et al., 2009, CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies., Leuk. Lymphoma
Hederer et al., 2000, The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells., Int. Immunol.
Quintás-Cardama et al., 2009, Targeted therapy for chronic lymphocytic leukemia., Target Oncol
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
James et al., 1999, 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen., J. Mol. Biol.
Gilliland et al., 1999, Elimination of the immunogenicity of therapeutic antibodies., J. Immunol.
Lin et al., 2005, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia., Blood
Brett et al., 1996, Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H., Immunology
Osterborg et al., 1997, Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)., Eur. J. Haematol.
Nagler et al., 1997, Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells., Bone Marrow Transplant.
Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

ALEMTUZUMAB CD52

Interaction Score: 120.71

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CAMPATH-1 antigen inhibitor

Trial Name Campath

PMIDs:
10573085 8981930 10520035 19479612 10744652 19343298 11752352 10366506 10092828

Sources:
NCI TEND TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions
ALEMTUZUMAB FCGR2C

Interaction Score: 7.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank
ALEMTUZUMAB FCGR2B

Interaction Score: 2.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank
ALEMTUZUMAB FCGR1A

Interaction Score: 2.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank
ALEMTUZUMAB CXCL12

Interaction Score: 1.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27173875

Sources:
PharmGKB
ALEMTUZUMAB FCGR2A

Interaction Score: 1.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15217834

Sources:
DrugBank
ALEMTUZUMAB FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8707338 9020367 9337053

Sources:
DrugBank
ALEMTUZUMAB FCGR3A

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15217834

Sources:
DrugBank

DrugBank: DB00087

Version: 5.1.7

Alternate Names:

ALEMTUZUMAB DrugBank Drug Name

216503-57-0 CAS Number

Campath Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Groups investigational

Publications:

White AL et al., 2013, FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs., Cancer Immunol Immunother

Lin et al., 2005, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia., Blood

Rebello et al., 1999, Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection., Transplantation

MyCancerGenome: ALEMTUZUMAB
- Version: 20-Jun-2017
Alternate Names:

ALEMTUZUMAB Generic Name

CAMPATH Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval B-cell chronic lymphocytic leukemia

Publications:
TEND: ALEMTUZUMAB
- Version: 01-August-2011
Alternate Names:

ALEMTUZUMAB Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 2001

Publications:
TdgClinicalTrial: ALEMTUZUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:
NCI: CAMPATH
- Version: 14-September-2017
Alternate Names:

C1681 NCI drug code

Drug Info:

Publications:

Wing et al., 1996, Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells., J. Clin. Invest.
PharmGKB: alemtuzumab
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA
GuideToPharmacology: 178103376
- Version: 29-September-2020
Alternate Names:

ALEMTUZUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Alemtuzumab
- Version: 2020.06.01
Alternate Names:

D01ZYG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201587
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201587
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	CAMPATH-1 antigen inhibitor
Trial Name	Campath

ALEMTUZUMAB	DrugBank Drug Name
216503-57-0	CAS Number
Campath	Drug Brand

Drug Type	biotech
Drug Groups	approved
Drug Groups	investigational

antibody (inhibitory)
inhibitor (inhibitory)

ALEMTUZUMAB Drug Record

ALEMTUZUMAB chembl:CHEMBL1201587 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction CAMPATH-1 antigen inhibitor Trial Name Campath

PMIDs: 10573085 8981930 10520035 19479612 10744652 19343298 11752352 10366506 10092828

Sources: NCI TEND TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23543215 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23543215 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23543215 17139284 17016423

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27173875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15217834

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8707338 9020367 9337053

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15217834

Sources: DrugBank

DrugBank: DB00087

Alternate Names: ALEMTUZUMAB DrugBank Drug Name 216503-57-0 CAS Number Campath Drug Brand

Drug Info: Drug Type biotech Drug Groups approved Drug Groups investigational

MyCancerGenome: ALEMTUZUMAB

Alternate Names: ALEMTUZUMAB Generic Name CAMPATH Trade Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval B-cell chronic lymphocytic leukemia

Publications:

TEND: ALEMTUZUMAB

Alternate Names: ALEMTUZUMAB Primary Drug Name

Drug Info: Drug Class antineoplastic agents Year of Approval 2001

Publications:

TdgClinicalTrial: ALEMTUZUMAB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval approved

Publications:

NCI: CAMPATH

Alternate Names: C1681 NCI drug code

Drug Info:

Publications: Wing et al., 1996, Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells., J. Clin. Invest.

PharmGKB: alemtuzumab

Alternate Names:

Drug Info:

Publications: Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

GuideToPharmacology: 178103376

Alternate Names: ALEMTUZUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Alemtuzumab

Alternate Names: D01ZYG TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201587

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201587

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction CAMPATH-1 antigen inhibitor

Trial Name Campath

PMIDs:
10573085 8981930 10520035 19479612 10744652 19343298 11752352 10366506 10092828

Sources:
NCI TEND TdgClinicalTrial TTD DrugBank MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
23543215 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
27173875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15217834

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
8707338 9020367 9337053

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15217834

Sources:
DrugBank

Alternate Names:

ALEMTUZUMAB DrugBank Drug Name

216503-57-0 CAS Number

Campath Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Groups investigational

Alternate Names:

ALEMTUZUMAB Generic Name

CAMPATH Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval B-cell chronic lymphocytic leukemia

Alternate Names:

ALEMTUZUMAB Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 2001

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

C1681 NCI drug code

Publications:

Wing et al., 1996, Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells., J. Clin. Invest.

Publications:

Butrym A et al., 2016, Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia., HLA

Alternate Names:

ALEMTUZUMAB GuideToPharmacology Ligand Name

Alternate Names:

D01ZYG TTD Drug ID